JAK3 抑制剂抑制多效的 ILC2s,并减弱耐固醇喘的作用
Jihyun Kim1,2, Jongho Ham1,2,3, Hye Ryun Kang2,4
1Laboratory of Mucosal Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
Science advances
|December 20, 2023
概括
第二组先天性淋巴细胞 (ILC2s) 可以在喘中对类固醇产生抗性,从而导致炎症. 用抑制剂准Janus激酶3 (JAK3) 提供了对抗类固醇喘的潜在治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类固醇是喘过敏气道炎症的主要治疗方法.
- 固醇耐药性喘仍然是一个重大的临床挑战.
- 2组先天性淋巴细胞 (ILC2s) 和T辅助细胞2 (TH2) 产生2型细胞因子,涉及喘病原性.
研究的目的:
- 为了研究肺部ILC2s在类固醇耐药喘中的作用.
- 确定ILC2s中类固醇耐药性的基础机制.
- 评估针对类固醇耐药喘中的Janus激酶3 (JAK3) 的治疗潜力.
主要方法:
- 在喘模型中分析ILC2s和TH2细胞.
- 在ILC2类固醇耐药性中研究信号通路 (JAK3/STAT).
- 在体外评估JAK3抑制剂对ILC2s的影响.
- 在喘模型中对JAK3抑制剂和类固醇联合治疗的体内评估.
主要成果:
- 肺部ILC2s,而不是TH2细胞,可以发展类固醇耐药性,在治疗期间持续.
- 多能IL-5+IL-13+IL-17A+ ILC2s与类固醇抵抗有关.
- 在获得ILC2类固醇耐药性方面,JAK3/STAT通路至关重要.
- 抑制JAK3降低了ILC2的存活率,增殖和细胞因子的产生,改善了喘.
- 结合JAK3抑制和类固醇有效治疗耐固醇喘.
结论:
- ILC2s是类固醇耐药喘的关键驱动因素.
- 针对JAK3/STAT途径是一个新的治疗策略.
- 与JAK3抑制剂和类固醇联合治疗对慢性喘管理有很大的前景.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
265
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
265
Antiasthma Drugs: Leukotriene Modifiers
315
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
315
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
Drugs Used in Lower Respiratory Disorders: Overview
449
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
449
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


